Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | TPI1 | P60174 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
| ▸ | PGK2 | P07205 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7655070 | 0.82 | PEPD (0.38) | CA4LPAR3LPAR1LPAR2PEPD | |
| SCHEMBL527061 | 0.79 | CA4 (0.39) | CA4LPAR3LPAR1LPAR2PEPD | |
| SCHEMBL2488147 | 0.75 | CA4 (0.43) | CA4PEPD | |
| SCHEMBL15858719 | 0.75 | LPAR3 (0.42) | LPAR3LPAR1LPAR2ENPP2 | |
| SCHEMBL9718192 | 0.74 | CA4 (0.34) | CA4LPAR3LPAR1LPAR2PEPD | |
| SCHEMBL15944089 | 0.74 | CYP4F2 (0.35) | CA4PEPD | |
| SCHEMBL28858128 | 0.73 | CA4 (0.42) | CA4PEPD | |
| SCHEMBL23466367 | 0.72 | FDPS (0.39) | CA4LPAR3LPAR1LPAR2SMPD1 | |
| SCHEMBL2475483 | 0.72 | DGAT1 (0.44) | — | |
| SCHEMBL11347820 | 0.71 | PEPD (0.33) | CA4LPAR3LPAR1LPAR2PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1775297-A2 | Adenosine receptor antagonists and methods of making and using the same | Biogen Idec MA, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1230241-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ENSINGER CAROL L | 2005-10-06 | — | — | US | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | BIOGEN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| US-6605600-B1 | Diuretics | BIOGEN, INCORPORATED | 2003-08-12 | — | — | US | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1230241-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034604-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0934281-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| US-5808120-A | Method of synthesis of retinoic acid | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1998017651-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA-A RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | CA4 1876/4885LPAR3 3115/4885LPAR1 1848/4885 |
| US-20050222179-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | CA4 2123/4885LPAR3 419/4885LPAR1 160/4885 |
| US-20030225038-A1 | Adenosine receptor antagonists and methods of making and using the same | ADORA1, ADORA2A, ADORA3 | CA4 2354/4885LPAR3 369/4885LPAR1 124/4885 |
| US-20080004293-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | ADORA1, ADORA2A, ADORA3 | CA4 2123/4885LPAR3 419/4885LPAR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.